CorMedix Inc. (CRMD) Stock News
Follow the latest CorMedix Inc. (CRMD) news and market headlines alongside the live CRMD price. Stay informed on what's moving CRMD.
News
Read Full Article Read Full Article - Read Full Article
Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11
Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.
- Read Full Article
Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13
Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
- Read Full Article
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.
- Read Full Article
Cormedix Q3 2026 Earnings Call Transcript
Cormedix (NASDAQ:CRMD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
- Read Full Article
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.09 loss by 55.56%, but revenues declined to $54.52 million from $104.28 million year-over-year. The stock has underperformed the market by 54.4% this year and carries a Zacks Rank #3 (Hold) rating. Techne (TECH), a peer in the medical testing industry, is expected to report earnings of $0.46 per share with modest revenue growth of 2.4%.
- Read Full Article
Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate
Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 133.33 percent decrease over earnings of $0.57 per share from the
- Read Full Article
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $337.061 million estimate.
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to CRMD, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.
